NEULANDLAB.NS Profit & Loss
Neuland Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:40
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹11.91 Bn | ₹15.59 Bn | ₹14.77 Bn | ₹20.23 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹0.10 Bn | ₹0.13 Bn | ₹0.21 Bn | ₹0.30 Bn | OtherIncome |
| Total Income | ₹12.01 Bn | ₹15.71 Bn | ₹14.97 Bn | ₹20.53 Bn | Income |
| Cost of Materials Consumed | ₹4.88 Bn | ₹6.32 Bn | ₹5.75 Bn | ₹8.20 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-0.10 Bn | ₹-0.55 Bn | ₹0.13 Bn | ₹-0.64 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹2.02 Bn | ₹2.57 Bn | ₹2.72 Bn | ₹3.41 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹0.13 Bn | ₹0.14 Bn | ₹0.08 Bn | ₹0.24 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹0.53 Bn | ₹0.60 Bn | ₹0.66 Bn | ₹0.92 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹2.39 Bn | ₹2.62 Bn | ₹2.94 Bn | ₹3.52 Bn | OtherExpenses |
| Total Expenses | ₹9.85 Bn | ₹11.70 Bn | ₹12.27 Bn | ₹15.64 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹2.16 Bn | ₹4.01 Bn | ₹2.70 Bn | ₹4.89 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Bn | ₹0.00 Bn | ₹0.76 Bn | ₹0.00 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹2.16 Bn | ₹4.01 Bn | ₹3.46 Bn | ₹4.89 Bn | ProfitBeforeTax |
| Tax Expense | ₹0.52 Bn | ₹1.01 Bn | ₹0.86 Bn | ₹1.25 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹1.64 Bn | ₹3.00 Bn | ₹2.60 Bn | ₹3.64 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | N/A | ₹0.00 Bn | ₹0.00 Bn | ₹3.64 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹127.45 | ₹233.89 | ₹202.74 | ₹283.71 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹127.45 | ₹233.89 | ₹202.74 | ₹283.71 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from NEULANDLAB.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).